Q2 25 EPS
$0.14
BEAT +3.70%
Est. $0.14
Q2 25 Revenue
$122.0M
BEAT +0.18%
Est. $121.8M
vs S&P Since Q2 25
-62.9%
TRAILING MARKET
ADMA -47.0% vs S&P +16.0%
Market Reaction
Did ADMA Beat Earnings? Q2 2025 Results
ADMA Biologics delivered a clean beat across both top and bottom lines in the second quarter of 2025, reporting earnings per share of $0.14 against a consensus estimate of $0.14, a 3.70% beat, while revenue of $121.98 million edged past the $121.77 m… Read more ADMA Biologics delivered a clean beat across both top and bottom lines in the second quarter of 2025, reporting earnings per share of $0.14 against a consensus estimate of $0.14, a 3.70% beat, while revenue of $121.98 million edged past the $121.77 million analyst forecast and rose 13.8% year over year. The headline growth understates the underlying momentum: stripping out a $12.60 million Medicaid rebate accrual reversal that boosted the year-ago period, organic revenue expanded roughly 29%. The primary engine behind the quarter's profitability was a richer mix of higher-margin immunoglobulin sales combined with manufacturing efficiencies, which lifted gross margin to 55.1% from 53.6%. A post-quarter $300 million debt refinancing further reduced interest costs, strengthening the company's financial footing heading into what management projects will be an accelerating second half. ADMA reaffirmed full-year 2025 revenue guidance of more than $500 million and its 2026 target of $625 million or more, with a longer-term pre-2030 revenue goal of at least $1.10 billion.
Key Takeaways
- • Continued adoption and utilization of ASCENIV by physicians, payers, and patients
- • More favorable mix of higher-margin immunoglobulin (IG) sales
- • Operational efficiencies that reduced manufacturing costs
- • Lower interest expense year-over-year
- • Record high-titer plasma collections from both internal and external sources
ADMA YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
ADMA Revenue by Segment
With YoY comparisons, source: SEC Filings
“The second quarter was another highly productive period for ADMA, highlighted by strong year-over-year underlying revenue and earnings growth, adjusting for a prior-year non-recurring item. We are confidently reaffirming all previously issued financial guidance, with growth rates anticipated to accelerate significantly in the second half of 2025 and beyond. Importantly, we commenced commercial-scale manufacturing with our FDA-approved yield enhancement process, and initial production batches are delivering the anticipated 20%+ increase in finished IG output. The successful initiation of yield-enhanced manufacturing marks a key inflection point—driving expected gross margin expansion, reinforcing ADMA's forecasted growth trajectory, and positioning the Company for an accelerating pace of revenue and earnings growth in the periods ahead.”
— Adam Grossman, Q2 2025 Earnings Press Release
ADMA Earnings Trends
ADMA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ADMA EPS Trend
Earnings per share: estimate vs actual
ADMA Revenue Trend
Quarterly revenue: estimate vs actual
ADMA Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.20 | $0.19 | -5.00% | $114.5M | -18.20% |
| Q4 25 BEAT FY | $0.20 | $0.20 | +0.00% | $139.2M | -0.46% |
| FY Full Year | — | $0.60 | — | $510.2M | — |
| Q3 25 MISS | $0.16 | $0.15 | -3.23% | $134.2M | +2.83% |
| Q2 25 BEAT | $0.14 | $0.14 | +3.70% | $122.0M | +0.18% |
| Q1 25 MISS | $0.13 | $0.11 | -15.38% | $114.8M | -1.37% |